Episode 102. The Controversy of Cefdinir in UTIs


Show Notes: Episode 102 – The Controversy of Cefdinir in UTIs

In this episode, we dive into the hot topic of using cefdinir, a third-generation oral cephalosporin antibiotic, in treating urinary tract infections (UTIs). Despite its low urine concentrations, cefdinir has shown clinical efficacy in treating UTIs, sparking a controversy that we explore in depth.

Key Topics:

Background on Cefdinir: We discuss the role of cefdinir in treating UTIs and why its use is controversial.

Review of Literature: We delve into several clinical trials and studies that have been conducted on the use of cefdinir for UTIs:
Cardinale et al: High efficacy and safety of cefdinir in UTI treatment.
Sader et al., 2005: Cefdinir showed high activity against common UTI pathogens.
Bonsu et al., 2006: High susceptibility of urinary pathogens to cefdinir.
Oishi et al., 2011: Prophylactic cefdinir could prevent recurrent UTIs in pediatric patients.
Leigh et al., 2000: Clinical cure rates and microbiologic response rates for cefdinir and cefaclor were statistically equivalent.
Kim et al., 2014: Cefdinir has low urine concentrations, which could potentially affect its efficacy in treating UTIs.
Davis et al., 2022: The study found that despite high resistance rates to some antibiotics in the U.S.-Mexico border region, cefdinir, along with amoxicillin/clavulanate, cefuroxime, and nitrofurantoin, showed lower resistance rates and could be effective for outpatient UTI treatment.

Clinical Pearls:
We share some key takeaways from the studies and discussions, including the role of cefazolin as the susceptibility surrogate for oral cephalosporins.

Discussion of Twitter Comments and Retweets: We discuss the results of a Twitter poll and the interesting discussions it sparked among healthcare professionals.

Check out the Twitter Poll on this topic: https://twitter.com/pharmso_hard/status/1667205066615410690


EMPoweRx Conference Homestudy Release: The EMPoweRx Conference Homestudy is now available! This is a great opportunity to learn from experts in the field at your own pace. Check it out at empowerx-conference.com.

PACUPrep BCEMP Question Bank Version 2.1 Release: The new version of the PACUPrep BCEMP Question Bank is now available at pharmacy-acutecareuniversity.com. This is a valuable resource for anyone preparing for the BCEMP exam.


2.       Cardinale B, et al. Retrospective Comparison of Cefdinir, Cephalexin, and Sulfamethoxazole-Trimethoprim in the Treatment of Outpatient Pediatric Urinary Tract Infections. Clin Pediatr (Phila). 2023 Jan;62(1):47-54. PMID: 35861216.

3.       Sader HS, et al. Antimicrobial activity of cefdinir (FK482), an orally administered cephalosporin, against pathogens isolated from respiratory tract and skin and soft tissue infections. Diagn Microbiol Infect Dis. 2005;51(1):27-33. Link

4.       Bonsu BK, et al. Susceptibility of recent bacterial isolates to cefdinir and selected antibiotics among children with urinary tract infections. Pediatr Emerg Care. 2006;22(1):18-21. Link

5.       Oishi T, et al. Prophylactic cefdinir for pediatric cases of complicated urinary tract infection. Pediatr Int. 2011;53(1):57-61. Link

6.       Leigh AP, et al. Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection. Clin Ther. 2000;22(7):818-825. Link

7.       Kim YC, et al. Effects of 1α,25-dihydroxyvitamin D3, the natural vitamin D receptor ligand, on the pharmacokinetics of cefdinir and cefadroxil, organic anion transporter substrates, in rat. J Pharm Sci. 2014;103(11):3793-3805. Link

8.       Nguyen HM, et al. Cefazolin as a class representative for oral cephalosporins and uncomplicated urinary tract infections caused by indicated Enterobacteriaceae. Diagn Microbiol Infect Dis. 2013;77(4):350-352. Link

9.       https://www.fda.gov/drugs/development-resources/rationale-fdas-position-use-cefazolin-breakpoints-surrogate-determining-breakpoints-oral.

10.   Gupta K,; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103-20. PMID: 21292654.

11. Coleman A et al. Antibiotic Utilization and Efficacy Associated With Treating Pediatric Urinary Tract Infections in Texas Medicaid Patients in the First Year of Life. Pediatr Infect Dis J. 2021 Nov 1;40(11):993-996. PMID: 34321440.

12. Davis WH, Magee MR, Monks SM, Geno KA, Crawford SB. Assessment of nationally recommended antibiotics for treatment of UTI in U.S.-Mexico border emergency departments. Am J Emerg Med. 2022 Nov;61:12-17. 14. PMID: 36027632


Jimmy L. Pruitt III, PharmD, BCPS, BCCCP

The Pharm So Hard Podcast is a show focused primarily on emergency medicine and hospital pharmacy related topics. To empower healthcare providers with the knowledge and skills they need to provide evidence-based, safe care for critically ill patients.

Posted On




Subscribe to our Newsletter

New Episodes on 1st, 2nd, 4th Tuedays

Stay Connected to Get The Latest Podcast Alerts

Want to learn more?

Pharmacy and Acute Care University

An e-learning platform that empowers healthcare providers with knowledge and skills so they can provide evidence-based, safe care for these types of patients.

Pin It on Pinterest

%d bloggers like this: